The Tissue and Cell Molecular Analysis Shared Resource provides research service for pathology, immunohistochemistry, in situ hybridization, digital image analysis, laser capture microdissection, and preparation of tissues for subsequent protein extraction for members of the Mayo Clinic Cancer Center. During 2002, this resource was used by more than 70 investigators at the Mayo Clinic and supported cancer research funded by more than 50 NCI-recognized grants. Several areas of service are being expanded and developed in the TACMA Shared Resource: 1) digital image analysis performed using a Bliss """"""""Virtual Microscopy"""""""" microscope and computer system from Bacus Laboratories will be available across all three Mayo sites via the Mayo intranet and shared server space, 2) technical protocols have been developed for detection of phosphorylation-state specific proteins for analysis of signaling pathways in paraffin embedded tissues, 3) protocols for simultaneous detection of two antigens are being developed, 4) the feasibility of using Zenon TM direct label probes for IHC is being investigated, 5) fluorescent probes are being used for subcellular localization of antigens in paraffin embedded tissues at a resolution much greater than is possible with calorimetric IHC detection chemistries that use brightfield microscopy. The services provided by the TACMA Shared Resource have been vital to cancer research at the Mayo Clinic since the inception of the MCCC. By expanding technical services and developing protocols for new probes, the TACMA resource can help Mayo investigators lead the way into the future of cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-30
Application #
6989941
Study Section
Subcommittee G - Education (NCI)
Project Start
2004-09-15
Project End
2009-02-28
Budget Start
2004-09-15
Budget End
2005-02-28
Support Year
30
Fiscal Year
2004
Total Cost
$65,575
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227

Showing the most recent 10 out of 1129 publications